Pulse Biosciences, Inc. (NASDAQ: PLSE)

$25.89 ▲ +0.35 (+1.37%)

As of May 22, 2026 04:00 PM

Sector: Healthcare Industry: Medical Instruments & Supplies CIK: 0001625101

Market Cap 1.72 Bn

P/E -31.15

Div. Yield 0.00

Add ratio to table...

About

Pulse Biosciences is a medical technology company specializing in the development and commercialization of its proprietary Nano-pulse Stimulation (NPS) technology, a novel energy modality that delivers nanosecond-duration electrical pulses to nonthermally ablate or clear targeted cells. Operating in the ablation device industry, the company focuses on addressing unmet medical needs across cardiology, soft tissue ablation, and other specialties by leveraging its patented nPulse System platform. NPS technology, particularly when used as Nanosecond...

Pulse Biosciences is a medical technology company specializing in the development and commercialization of its proprietary Nano-pulse Stimulation (NPS) technology, a novel energy modality that delivers nanosecond-duration electrical pulses to nonthermally ablate or clear targeted cells. Operating in the ablation device industry, the company focuses on addressing unmet medical needs across cardiology, soft tissue ablation, and other specialties by leveraging its patented nPulse System platform. NPS technology, particularly when used as Nanosecond Pulsed-Field Ablation (nsPFA), is designed to treat conditions such as atrial fibrillation (AF) and benign thyroid nodules with precision, minimizing collateral damage to surrounding tissues.

The company generates revenue primarily through the sale of its nPulse System and associated disposable applicators, such as the Vybrance Percutaneous Electrode System, which received FDA 510(k) clearance in 2024. These products are marketed to healthcare providers for use in soft tissue ablation and, in the future, cardiac procedures. While Pulse Biosciences previously commercialized its technology for dermatologic applications, it has since shifted its strategic focus to higher-growth markets, including cardiology and surgical ablation, where it anticipates significant demand. Revenue is also derived from early commercial agreements, pilot programs, and partnerships with medical institutions evaluating its systems.

The company operates through the following segments:

• Soft Tissue Ablation: This segment focuses on the treatment of benign lesions and nodules, primarily through the Vybrance Percutaneous Electrode System. The system consists of disposable needle electrodes used with the nPulse Console to deliver nsPFA energy for precise, nonthermal ablation of soft tissue, such as benign thyroid nodules. The company has initiated clinical trials, including the PRECISE BTN study, to generate evidence supporting the safety and effectiveness of this technology, with over 300 patient procedures completed to date.

• Cardiac Ablation: This segment targets the treatment of atrial fibrillation (AF) and other cardiac arrhythmias using nsPFA technology. Pulse Biosciences is developing two key products: the nPulse Cardiac Surgical Clamp, designed for use by cardiac surgeons during the Cox-Maze procedure, and the nPulse Cardiac Catheter System, intended for electrophysiologists performing endocardial ablation. Both products aim to provide faster, safer, and more effective ablation compared to traditional thermal modalities. The company has received FDA Breakthrough Device Designation for its cardiac surgery system and has initiated pivotal clinical trials for both products.

• Platform Technology: The nPulse Console serves as the foundational platform for the company’s ablation systems, enabling the delivery of nsPFA energy across multiple medical specialties. Initially cleared for dermatologic procedures, the console is now being adapted for cardiac and soft tissue applications. While commercial efforts in dermatology have ceased, the console remains integral to the company’s broader strategic initiatives.

Pulse Biosciences operates in a highly competitive medical device industry, facing established players such as Abbott Laboratories, AtriCure, Boston Scientific, Johnson & Johnson (Biosense Webster), and Medtronic. These competitors offer a range of ablation products, including thermal modalities like radiofrequency and cryoablation, as well as emerging pulsed-field ablation (PFA) technologies. Despite its smaller size and limited resources compared to these incumbents, Pulse Biosciences differentiates itself through its nsPFA technology, which delivers shorter pulse durations than traditional PFA, potentially offering improved precision, reduced scarring, and enhanced safety. The company’s intellectual property portfolio, comprising over 250 issued patents and 180 pending applications, further strengthens its competitive position by protecting its core technology and applications through 2042.

The company’s customer base primarily includes hospitals, surgical centers, and specialized medical practitioners, such as cardiac surgeons, electrophysiologists, and interventional radiologists. Pulse Biosciences has engaged with leading clinicians and institutions, including Professor Stefano Spiezia at Ospedale del Mare in Naples, Dr. Andrea Natale at the Texas Cardiac Arrhythmia Institute, and Dr. Vivek Reddy at Mount Sinai Fuster Heart Hospital, to conduct clinical studies and gather feedback on its products. These collaborations aim to validate the technology and support its commercial adoption in the United States and Europe.

Investment thesis

Bull case

The company’s initial revenue of $86,000 is an almost negligible fraction of the procedural volume, which already exceeds 200 patients in the third quarter. Most of these cases are conducted under pilot programs or ongoing clinical studies, meaning the true commercial potential is substantially hidden. The market may therefore be underestimating the revenue upside once the pipeline shifts from study to fully commercialized procedures. As adoption rates rise, the incremental revenue per procedure could accelerate, creating a compounding effect that is not yet reflected in the current financials.
The early clinical data for the nPulse Cardiac Catheter demonstrate an impressive 100% procedural success at six months and 96% at twelve months with only a 1.3% serious adverse event rate. These figures far exceed the typical 20‑25% recurrence rate observed with radiofrequency and cryoablation, indicating a strong therapeutic advantage. The durability of the lesions, as evidenced by 3‑month mapping data, suggests that long‑term efficacy will be maintained, reducing repeat procedures and enhancing patient satisfaction. Such robust outcomes could unlock preferential reimbursement positioning and accelerate market penetration among electrophysiology practices.
nsPFA’s non‑thermal mechanism translates into fewer collateral injuries, lower risk of phrenic nerve damage, and a reduced likelihood of pulmonary vein stenosis. The clinical implications are twofold: a safer profile that appeals to clinicians and a shorter procedural workflow that lowers operating room time and cost. Payors are increasingly attentive to procedural efficiency and safety metrics when determining coverage levels, so the technology’s intrinsic advantages could drive faster payer adoption. Over time, the economic benefits could reinforce the value proposition and create a self‑reinforcing cycle of utilization.
The company’s multi‑indication strategy—targeting thyroid nodules, atrial fibrillation, and surgical ablation—creates a diversified revenue moat. Success in one domain can provide data and credibility that accelerate acceptance in the others. For example, positive safety outcomes in atrial fibrillation can reassure surgeons contemplating the cardiac clamp for concomitant procedures. This cross‑application synergy reduces overall business risk by spreading it across distinct therapeutic areas.
The appointment of Maria Sainz to the board signals a strategic intent to strengthen commercialization capabilities. Her track record with high‑growth medical device firms suggests she will help refine go‑to‑market strategies and negotiate pivotal partnerships. The board’s enhanced expertise can accelerate the company’s transition from clinical validation to commercial deployment. Market participants may not fully appreciate the immediate impact of this leadership change on future execution.

The company’s initial revenue of $86,000 is an almost negligible fraction of the procedural volume, which already exceeds 200 patients in the third quarter. Most of these cases are conducted under pilot programs or ongoing clinical studies, meaning the true commercial potential is substantially hidden. The market may therefore be underestimating the revenue upside once the pipeline shifts from study to fully commercialized procedures. As adoption rates rise, the incremental revenue per procedure could accelerate, creating a compounding effect that is not yet reflected in the current financials.
The early clinical data for the nPulse Cardiac Catheter demonstrate an impressive 100% procedural success at six months and 96% at twelve months with only a 1.3% serious adverse event rate. These figures far exceed the typical 20‑25% recurrence rate observed with radiofrequency and cryoablation, indicating a strong therapeutic advantage. The durability of the lesions, as evidenced by 3‑month mapping data, suggests that long‑term efficacy will be maintained, reducing repeat procedures and enhancing patient satisfaction. Such robust outcomes could unlock preferential reimbursement positioning and accelerate market penetration among electrophysiology practices.
nsPFA’s non‑thermal mechanism translates into fewer collateral injuries, lower risk of phrenic nerve damage, and a reduced likelihood of pulmonary vein stenosis. The clinical implications are twofold: a safer profile that appeals to clinicians and a shorter procedural workflow that lowers operating room time and cost. Payors are increasingly attentive to procedural efficiency and safety metrics when determining coverage levels, so the technology’s intrinsic advantages could drive faster payer adoption. Over time, the economic benefits could reinforce the value proposition and create a self‑reinforcing cycle of utilization.
The company’s multi‑indication strategy—targeting thyroid nodules, atrial fibrillation, and surgical ablation—creates a diversified revenue moat. Success in one domain can provide data and credibility that accelerate acceptance in the others. For example, positive safety outcomes in atrial fibrillation can reassure surgeons contemplating the cardiac clamp for concomitant procedures. This cross‑application synergy reduces overall business risk by spreading it across distinct therapeutic areas.
The appointment of Maria Sainz to the board signals a strategic intent to strengthen commercialization capabilities. Her track record with high‑growth medical device firms suggests she will help refine go‑to‑market strategies and negotiate pivotal partnerships. The board’s enhanced expertise can accelerate the company’s transition from clinical validation to commercial deployment. Market participants may not fully appreciate the immediate impact of this leadership change on future execution.

Bear case

Net losses of $19.4 million in Q3 reflect a high burn environment that is not yet offset by meaningful revenue. Stock‑based compensation rose to $5.6 million, constituting 38% of the year‑over‑year increase in expenses, signaling potential dilution and shareholder value erosion. The company’s cash runway, while sufficient at present, is being consumed at a rate that may necessitate additional fundraising before commercialization yields revenue. If the company cannot secure strategic financing or equity infusions, it risks running out of capital while still investing heavily in clinical studies.
The bulk of procedural volume is still confined to pilot programs and clinical trials, with only a modest $86,000 in revenue. The conversion of these pilots into fully commercial accounts is uncertain; the company has yet to demonstrate that practitioners will adopt the technology at scale beyond early adopters. If the transition stalls, the revenue pipeline will remain thin, limiting the ability to cover operating costs and invest in growth. This scenario exposes the business to a prolonged period of negative earnings and cash depletion.
Payer coverage remains unestablished for many of the company’s indications. While preliminary claims data are positive, the absence of a clear reimbursement framework could delay or reduce the reimbursement rates for procedures performed under the technology. Payers may demand robust real‑world evidence before granting full coverage, and delays in reimbursement approvals could compress margins for early adopters. The company’s ability to secure favorable payer terms is therefore a critical, but currently uncertain, driver of revenue.
Although the company has secured IDE approvals and breakthrough status, final FDA clearance is still pending. The timeline for clearance can be unpredictable, and any delays—whether due to additional data requirements or adverse safety findings—could postpone market entry by months or even years. A delayed approval would postpone the onset of commercial revenue and prolong the company’s reliance on internal funding. Such regulatory uncertainty is a substantial risk that is not fully priced into the current valuation.
The atrial fibrillation market is already crowded with established technologies such as cryoablation and radiofrequency ablation, as well as emerging competitors exploring nanosecond pulse field ablation. Pulse’s advantage lies in early efficacy data, yet competitors may launch their own devices with similar or superior performance, eroding Pulse’s potential market share. In a commoditized market, the ability to maintain pricing power is fragile, especially if payers negotiate discounts based on comparative effectiveness data. The company faces a challenging competitive landscape that could constrain growth.

Net losses of $19.4 million in Q3 reflect a high burn environment that is not yet offset by meaningful revenue. Stock‑based compensation rose to $5.6 million, constituting 38% of the year‑over‑year increase in expenses, signaling potential dilution and shareholder value erosion. The company’s cash runway, while sufficient at present, is being consumed at a rate that may necessitate additional fundraising before commercialization yields revenue. If the company cannot secure strategic financing or equity infusions, it risks running out of capital while still investing heavily in clinical studies.
The bulk of procedural volume is still confined to pilot programs and clinical trials, with only a modest $86,000 in revenue. The conversion of these pilots into fully commercial accounts is uncertain; the company has yet to demonstrate that practitioners will adopt the technology at scale beyond early adopters. If the transition stalls, the revenue pipeline will remain thin, limiting the ability to cover operating costs and invest in growth. This scenario exposes the business to a prolonged period of negative earnings and cash depletion.
Payer coverage remains unestablished for many of the company’s indications. While preliminary claims data are positive, the absence of a clear reimbursement framework could delay or reduce the reimbursement rates for procedures performed under the technology. Payers may demand robust real‑world evidence before granting full coverage, and delays in reimbursement approvals could compress margins for early adopters. The company’s ability to secure favorable payer terms is therefore a critical, but currently uncertain, driver of revenue.
Although the company has secured IDE approvals and breakthrough status, final FDA clearance is still pending. The timeline for clearance can be unpredictable, and any delays—whether due to additional data requirements or adverse safety findings—could postpone market entry by months or even years. A delayed approval would postpone the onset of commercial revenue and prolong the company’s reliance on internal funding. Such regulatory uncertainty is a substantial risk that is not fully priced into the current valuation.
The atrial fibrillation market is already crowded with established technologies such as cryoablation and radiofrequency ablation, as well as emerging competitors exploring nanosecond pulse field ablation. Pulse’s advantage lies in early efficacy data, yet competitors may launch their own devices with similar or superior performance, eroding Pulse’s potential market share. In a commoditized market, the ability to maintain pricing power is fragile, especially if payers negotiate discounts based on comparative effectiveness data. The company faces a challenging competitive landscape that could constrain growth.

Peer comparison

Companies in the Medical Instruments & Supplies

S.No.	Ticker	Company	Market Cap	P/E	P/S	Total Debt (Qtr)
1	ISRG	Intuitive Surgical Inc	156.17 Bn	52.64	14.76	-
2	BDX	Becton Dickinson & Co	41.51 Bn	29.74	1.94	17.28 Bn
3	RMD	Resmed Inc	30.43 Bn	20.13	5.50	0.26 Bn
4	WST	West Pharmaceutical Services Inc	22.78 Bn	42.07	7.07	0.20 Bn
5	SOLV	Solventum Corp	13.39 Bn	9.37	1.62	5.08 Bn
6	COO	Cooper Companies, Inc.	12.33 Bn	31.01	2.97	2.50 Bn
7	ALGN	Align Technology Inc	11.65 Bn	27.31	2.84	-
8	BAX	Baxter International Inc	9.81 Bn	-72.70	0.91	9.46 Bn

Research Tools

Developers

Pulse Biosciences, Inc. (NASDAQ: PLSE)

About

Investment thesis

Bull case

Bear case

Peer comparison

Research Tools

Developers

Pulse Biosciences, Inc. (NASDAQ: PLSE)

About

Investment thesis

Bull case

Bear case

Peer comparison

Create an account

Sign In

Reset Password